Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 12341-12350 Newer>

The Motley Fool February 9, 2006 Rick Aristotle Munarriz	Cedar Fair's Seasonal Makeover The regional park operator gears up to rely less on the telltale third quarter. Investors, take note.
The Motley Fool February 9, 2006 Rick Aristotle Munarriz	Bon Voyage, Vonage The VoIP leader files to go public, but the company's current financials don't look too appealing. It's important for Vonage to enter the market at a reasonable price, especially now that it faces greater risk from the Grandbaby Bells. Let's hope that Vonage isn't making the call too late.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
The Motley Fool February 9, 2006	Dueling Fools: Intuitive Surgical Intuitive Surgical has been a big winner, more than doubling over the past year, but will the good times continue?
The Motley Fool February 9, 2006 Stephen D. Simpson	Dentsply: Often Overlooked, but Solid Can the dental-care company reclaim its past growth rates? Investors, take note.
The Motley Fool February 9, 2006 W.D. Crotty	Dueling Fools: Intuitive Surgical Bear Rebuttal It's an interesting company, but until the stock price gets trimmed even further, the valuation is just too high.
The Motley Fool February 9, 2006 Robert Aronen	Shine On, You Crazy Diamond Diamond Offshore's fourth-quarter results bury the analysts' estimates. But do these shares still have come upside left?
The Motley Fool February 9, 2006 Stephen D. Simpson	Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough.
The Motley Fool February 9, 2006 Stephen D. Simpson	Aexcellence From Aetna Low medical costs and good cash flow make this stock worth watching.
The Motley Fool February 9, 2006 Stephen D. Simpson	Growth Not Enough for Smith & Nephew This orthopedic company has market-leading growth, but just not enough cash flow. Investors shouldn't get too excited about these shares.
<Older 12341-12350 Newer> Return to current articles.